Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.

Richmond CS, Vallatharasu Y, Deviley JA, Vos CR, Parsons BM, Kenny PA.

Exp Mol Pathol. 2019 Oct;110:104260. doi: 10.1016/j.yexmp.2019.104260. Epub 2019 May 11.

PMID:
31082388
2.

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.

Fricke SL, Payne SN, Favreau PF, Kratz JD, Pasch CA, Foley TM, Yueh AE, Van De Hey DR, Depke MG, Korkos DP, Sha GC, DeStefanis RA, Clipson L, Burkard ME, Lemmon KK, Parsons BM, Kenny PA, Matkowskyj KA, Newton MA, Skala MC, Deming DA.

Mol Cancer Ther. 2019 Feb;18(2):346-355. doi: 10.1158/1535-7163.MCT-18-0510. Epub 2018 Nov 13.

PMID:
30425131
3.

Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth.

Mao SPH, Park M, Cabrera RM, Christin JR, Karagiannis GS, Oktay MH, Zaiss DMW, Abrams SI, Guo W, Condeelis JS, Kenny PA, Segall JE.

Breast Cancer Res. 2018 Oct 26;20(1):131. doi: 10.1186/s13058-018-1057-0.

4.

Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells.

Emmanuel N, Lofgren KA, Peterson EA, Meier DR, Jung EH, Kenny PA.

Anticancer Res. 2018 Aug;38(8):4435-4441. doi: 10.21873/anticanres.12745.

5.

The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.

Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shellooe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA, Verma AK.

JCI Insight. 2018 Jul 26;3(14). pii: 120422. doi: 10.1172/jci.insight.120422. eCollection 2018 Jul 26.

6.

Adaptation of an amplicon-based human cancer next-generation sequencing panel assay for murine tumors.

Meier DR, Lofgren KA, Gurda GT, Kenny PA.

Anal Biochem. 2018 Jun 15;551:26-28. doi: 10.1016/j.ab.2018.05.007. Epub 2018 May 10.

PMID:
29752895
7.

Assessment of the TRPM8 inhibitor AMTB in breast cancer cells and its identification as an inhibitor of voltage gated sodium channels.

Yapa KTDS, Deuis J, Peters AA, Kenny PA, Roberts-Thomson SJ, Vetter I, Monteith GR.

Life Sci. 2018 Apr 1;198:128-135. doi: 10.1016/j.lfs.2018.02.030. Epub 2018 Feb 26.

PMID:
29496495
8.

Oncosis and apoptosis induction by activation of an overexpressed ion channel in breast cancer cells.

Peters AA, Jamaludin SYN, Yapa KTDS, Chalmers S, Wiegmans AP, Lim HF, Milevskiy MJG, Azimi I, Davis FM, Northwood KS, Pera E, Marcial DL, Dray E, Waterhouse NJ, Cabot PJ, Gonda TJ, Kenny PA, Brown MA, Khanna KK, Roberts-Thomson SJ, Monteith GR.

Oncogene. 2017 Nov 16;36(46):6490-6500. doi: 10.1038/onc.2017.234. Epub 2017 Jul 31.

PMID:
28759041
9.

Genomic analysis of melanoma evolution following a 30-year disease-free interval.

Miller JJ, Lofgren KA, Hughes SR, Cash SE, Kenny PA.

J Cutan Pathol. 2017 Sep;44(9):805-808. doi: 10.1111/cup.12989. Epub 2017 Jul 19.

PMID:
28628281
10.

Amphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ERα-Positive Breast Cancer.

Peterson EA, Jenkins EC, Lofgren KA, Chandiramani N, Liu H, Aranda E, Barnett M, Kenny PA.

Cancer Res. 2015 Nov 15;75(22):4830-8. doi: 10.1158/0008-5472.CAN-15-0709. Epub 2015 Nov 2.

11.

Altered purinergic receptor-Ca²⁺ signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells.

Azimi I, Beilby H, Davis FM, Marcial DL, Kenny PA, Thompson EW, Roberts-Thomson SJ, Monteith GR.

Mol Oncol. 2016 Jan;10(1):166-78. doi: 10.1016/j.molonc.2015.09.006. Epub 2015 Sep 25.

12.

Comparative analysis of GATA3 mutation profiles between Asian and Western patients with breast cancer. Is there really a difference?

Chandiramani N, Kenny PA.

Cancer. 2014 Sep 1;120(17):2778-9. doi: 10.1002/cncr.28782. Epub 2014 Jun 4. No abstract available.

13.

PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis.

So PL, Wang GY, Wang K, Chuang M, Chiueh VC, Kenny PA, Epstein EH Jr.

Cancer Prev Res (Phila). 2014 Apr;7(4):407-17. doi: 10.1158/1940-6207.CAPR-13-0304. Epub 2014 Jan 21.

14.

Bisected, complex N-glycans and galectins in mouse mammary tumor progression and human breast cancer.

Miwa HE, Koba WR, Fine EJ, Giricz O, Kenny PA, Stanley P.

Glycobiology. 2013 Dec;23(12):1477-90. doi: 10.1093/glycob/cwt075. Epub 2013 Sep 13.

15.

Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo.

Zhou ZN, Sharma VP, Beaty BT, Roh-Johnson M, Peterson EA, Van Rooijen N, Kenny PA, Wiley HS, Condeelis JS, Segall JE.

Oncogene. 2014 Jul 17;33(29):3784-93. doi: 10.1038/onc.2013.363. Epub 2013 Sep 9.

16.

Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls.

Peterson EA, Pectasides E, Shabbeer S, Wiechmann L, Sparano JA, Kenny PA.

Exp Hematol Oncol. 2013 Sep 8;2(1):25. doi: 10.1186/2162-3619-2-25.

17.

TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion.

Giricz O, Calvo V, Peterson EA, Abouzeid CM, Kenny PA.

Int J Cancer. 2013 Dec 1;133(11):2587-95. doi: 10.1002/ijc.28295. Epub 2013 Jun 21.

18.

Translating genomic research into clinical practice: promise and pitfalls.

Sparano JA, Ostrer H, Kenny PA.

Am Soc Clin Oncol Educ Book. 2013:15-23. doi: 10.1200/EdBook_AM.2013.33.15. Review.

19.

Mitochondrial calcium uniporter silencing potentiates caspase-independent cell death in MDA-MB-231 breast cancer cells.

Curry MC, Peters AA, Kenny PA, Roberts-Thomson SJ, Monteith GR.

Biochem Biophys Res Commun. 2013 May 10;434(3):695-700. doi: 10.1016/j.bbrc.2013.04.015. Epub 2013 Apr 18.

PMID:
23602897
20.

Visualizing movement in the tumor microenvironment landscape.

Calvo V, Kenny PA.

Breast Cancer Res. 2013 Jan 15;15(1):301. doi: 10.1186/bcr3359.

21.

Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients.

Patsialou A, Wang Y, Lin J, Whitney K, Goswami S, Kenny PA, Condeelis JS.

Breast Cancer Res. 2012 Oct 31;14(5):R139. doi: 10.1186/bcr3344.

22.

Clarification of the C-terminal proteolytic processing site of human Amphiregulin.

Levano KS, Kenny PA.

FEBS Lett. 2012 Sep 21;586(19):3500-2. doi: 10.1016/j.febslet.2012.07.078. Epub 2012 Aug 9.

23.

FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice.

Lee SY, Meier R, Furuta S, Lenburg ME, Kenny PA, Xu R, Bissell MJ.

J Clin Invest. 2012 Sep;122(9):3211-20. doi: 10.1172/JCI60498. Epub 2012 Aug 13.

24.

Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer.

Peters AA, Simpson PT, Bassett JJ, Lee JM, Da Silva L, Reid LE, Song S, Parat MO, Lakhani SR, Kenny PA, Roberts-Thomson SJ, Monteith GR.

Mol Cancer Ther. 2012 Oct;11(10):2158-68. doi: 10.1158/1535-7163.MCT-11-0965. Epub 2012 Jul 17.

25.

Distinct regulation of cytoplasmic calcium signals and cell death pathways by different plasma membrane calcium ATPase isoforms in MDA-MB-231 breast cancer cells.

Curry MC, Luk NA, Kenny PA, Roberts-Thomson SJ, Monteith GR.

J Biol Chem. 2012 Aug 17;287(34):28598-608. doi: 10.1074/jbc.M112.364737. Epub 2012 Jun 25.

26.

Normal range of serum Amphiregulin in healthy adult human females.

Peterson EA, Shabbeer S, Kenny PA.

Clin Biochem. 2012 Apr;45(6):460-3. doi: 10.1016/j.clinbiochem.2011.12.029. Epub 2012 Jan 28.

PMID:
22306169
27.

GRB7 is required for triple-negative breast cancer cell invasion and survival.

Giricz O, Calvo V, Pero SC, Krag DN, Sparano JA, Kenny PA.

Breast Cancer Res Treat. 2012 Jun;133(2):607-15. doi: 10.1007/s10549-011-1822-6. Epub 2011 Oct 18.

PMID:
22005836
28.

Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity.

Giricz O, Reynolds PA, Ramnauth A, Liu C, Wang T, Stead L, Childs G, Rohan T, Shapiro N, Fineberg S, Kenny PA, Loudig O.

J Pathol. 2012 Jan;226(1):108-19. doi: 10.1002/path.2978. Epub 2011 Sep 26.

PMID:
21953071
29.

Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer.

Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW Jr, Gray R.

Clin Cancer Res. 2011 Nov 15;17(22):7194-203. doi: 10.1158/1078-0432.CCR-10-3357. Epub 2011 Sep 20.

30.

Remodeling of purinergic receptor-mediated Ca2+ signaling as a consequence of EGF-induced epithelial-mesenchymal transition in breast cancer cells.

Davis FM, Kenny PA, Soo ET, van Denderen BJ, Thompson EW, Cabot PJ, Parat MO, Roberts-Thomson SJ, Monteith GR.

PLoS One. 2011;6(8):e23464. doi: 10.1371/journal.pone.0023464. Epub 2011 Aug 5.

31.

Breast cancer subtypes express distinct receptor repertoires for tumor-associated macrophage derived cytokines.

Levano KS, Jung EH, Kenny PA.

Biochem Biophys Res Commun. 2011 Jul 22;411(1):107-10. doi: 10.1016/j.bbrc.2011.06.102. Epub 2011 Jun 25.

PMID:
21712030
32.

Illumina whole-genome complementary DNA-mediated annealing, selection, extension and ligation platform: assessing its performance in formalin-fixed, paraffin-embedded samples and identifying invasion pattern-related genes in oral squamous cell carcinoma.

Loudig O, Brandwein-Gensler M, Kim RS, Lin J, Isayeva T, Liu C, Segall JE, Kenny PA, Prystowsky MB.

Hum Pathol. 2011 Dec;42(12):1911-22. doi: 10.1016/j.humpath.2011.02.011. Epub 2011 Jun 17.

PMID:
21683979
33.

ORAI1-mediated calcium influx in lactation and in breast cancer.

McAndrew D, Grice DM, Peters AA, Davis FM, Stewart T, Rice M, Smart CE, Brown MA, Kenny PA, Roberts-Thomson SJ, Monteith GR.

Mol Cancer Ther. 2011 Mar;10(3):448-60. doi: 10.1158/1535-7163.MCT-10-0923. Epub 2011 Jan 11.

34.

Store-independent activation of Orai1 by SPCA2 in mammary tumors.

Feng M, Grice DM, Faddy HM, Nguyen N, Leitch S, Wang Y, Muend S, Kenny PA, Sukumar S, Roberts-Thomson SJ, Monteith GR, Rao R.

Cell. 2010 Oct 1;143(1):84-98. doi: 10.1016/j.cell.2010.08.040.

35.

Golgi calcium pump secretory pathway calcium ATPase 1 (SPCA1) is a key regulator of insulin-like growth factor receptor (IGF1R) processing in the basal-like breast cancer cell line MDA-MB-231.

Grice DM, Vetter I, Faddy HM, Kenny PA, Roberts-Thomson SJ, Monteith GR.

J Biol Chem. 2010 Nov 26;285(48):37458-66. doi: 10.1074/jbc.M110.163329. Epub 2010 Sep 13.

36.

Clinical application of gene expression profiling in breast cancer.

Sparano JA, Fazzari M, Kenny PA.

Surg Oncol Clin N Am. 2010 Jul;19(3):581-606. doi: 10.1016/j.soc.2010.03.008. Review.

PMID:
20620929
37.

Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture.

Han J, Chang H, Giricz O, Lee GY, Baehner FL, Gray JW, Bissell MJ, Kenny PA, Parvin B.

PLoS Comput Biol. 2010 Feb 26;6(2):e1000684. doi: 10.1371/journal.pcbi.1000684.

38.

Endothelial cell migration and vascular endothelial growth factor expression are the result of loss of breast tissue polarity.

Chen A, Cuevas I, Kenny PA, Miyake H, Mace K, Ghajar C, Boudreau A, Bissell MJ, Boudreau N.

Cancer Res. 2009 Aug 15;69(16):6721-9. doi: 10.1158/0008-5472.CAN-08-4069. Epub 2009 Aug 4. Erratum in: Cancer Res. 2010 Aug 1;70(15):6398. Bissell, Mina [corrected to Bissell, Mina J].

39.

The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.

Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ.

Mol Oncol. 2007 Jun;1(1):84-96. doi: 10.1016/j.molonc.2007.02.004.

40.

Localization of plasma membrane and secretory calcium pumps in the mammary gland.

Faddy HM, Smart CE, Xu R, Lee GY, Kenny PA, Feng M, Rao R, Brown MA, Bissell MJ, Roberts-Thomson SJ, Monteith GR.

Biochem Biophys Res Commun. 2008 May 9;369(3):977-81. doi: 10.1016/j.bbrc.2008.03.003. Epub 2008 Mar 10.

41.

Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer.

Kenny PA.

Expert Opin Ther Targets. 2007 Oct;11(10):1287-98. Review.

PMID:
17907959
42.

Three-dimensional extracellular matrix culture models of EGFR signalling and drug response.

Kenny PA.

Biochem Soc Trans. 2007 Aug;35(Pt 4):665-8. Review.

PMID:
17635116
43.

TACE: a new target in epidermal growth factor receptor dependent tumors.

Kenny PA.

Differentiation. 2007 Nov;75(9):800-8. Epub 2007 Jul 2. Review.

PMID:
17608729
44.

ERalpha-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis.

McBryan J, Howlin J, Kenny PA, Shioda T, Martin F.

Oncogene. 2007 Sep 27;26(44):6406-19. Epub 2007 May 7.

PMID:
17486082
45.

Targeting the tumor microenvironment.

Kenny PA, Lee GY, Bissell MJ.

Front Biosci. 2007 May 1;12:3468-74. Review.

46.

Three-dimensional culture models of normal and malignant breast epithelial cells.

Lee GY, Kenny PA, Lee EH, Bissell MJ.

Nat Methods. 2007 Apr;4(4):359-65.

47.

Targeting TACE-dependent EGFR ligand shedding in breast cancer.

Kenny PA, Bissell MJ.

J Clin Invest. 2007 Feb;117(2):337-45. Epub 2007 Jan 11.

48.

Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT?

Radisky DC, Kenny PA, Bissell MJ.

J Cell Biochem. 2007 Jul 1;101(4):830-9. Review.

50.

Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer.

Fournier MV, Martin KJ, Kenny PA, Xhaja K, Bosch I, Yaswen P, Bissell MJ.

Cancer Res. 2006 Jul 15;66(14):7095-102.

Supplemental Content

Loading ...
Support Center